1. Design and activity evaluation of new EGFR tyrosine kinase inhibitors containing cyclic polyamines.
- Author
-
Guo LL, Zhang YH, Zuo JF, Cheng Y, Chen G, and Li C
- Subjects
- Humans, Structure-Activity Relationship, Cell Line, Tumor, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Antineoplastic Agents chemical synthesis, Molecular Structure, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Cell Proliferation drug effects, Tyrosine Kinase Inhibitors, ErbB Receptors antagonists & inhibitors, ErbB Receptors metabolism, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors chemistry, Protein Kinase Inhibitors chemical synthesis, Polyamines chemistry, Polyamines pharmacology, Drug Design
- Abstract
The EGFR-TK pathway is pivotal in non-small-cell lung cancer (NSCLC) treatment, drugs targeting both EGFR wild-type and mutant tumor cells are still urgently needed. The focus of our study is on ATP-competitive inhibitors crucial for NSCLC therapy, specifically targeting the epidermal growth factor receptor (EGFR). A series of derivatives of Erlotinib and Icotinib were developed by incorporating a macrocyclic polyamine into a quinazoline scaffold to enhance their inhibitory activity against drug-resistant cells. The compounds exhibit modest activity against EGFR triple mutants (EGFR
del 19 /T790M/C797S ). Compound b demonstrated slightly improved inhibition activity against PC-9d el19/T790M/C797S (IC50 = 496.3 nM). This could provide some insights for optimizing EGFR inhibitors, particularly in the context of EGFR triple mutants., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF